Sapient Launches Proteomics Atlas of Normal Human Tissue Biology to De-risk Target Selection and On-Target, Off-Tissue Safety Assessment

June 9, 2026 – San Diego, CA – Sapient, a leader in multi-omics data generation for biomarker discovery and clinical insight delivery, has launched its DynamiQ™ Normal Human Tissue Proteomics Atlas as a comprehensive reference map of protein expression, signaling activity, cell surface accessibility, immune biology, and resistance pathways across 12,000+ proteins in diverse normal human tissues.

The atlas enables drug development teams to query target protein expression across more than 15 normal human tissues – including heart, liver, lung, kidney, and other primary organs associated with dose-limiting toxicities – to quantify expression relative to tumor or diseased tissue and identify organs at risk for on-target, off-tissue toxicity. Candidate targets can be rank-ordered based on tumor-to-normal expression ratios to prioritize those with favorable therapeutic index profiles. Baseline signaling, immune, and resistance pathway data further enables assessment of organ-level vulnerabilities and potential immune-related adverse events, supporting proactive evaluation of safety liabilities before moving to clinical phases.

Using Sapient’s mass spectrometry-based proteomics platform, each tissue is profiled across key biological dimensions: global protein expression across 12,000+ protein groups via DiscoverySeek™; cell surface protein expression via SurfaceSeek™; phosphorylation-driven signaling pathway activity via SignalingSeek™; immune cell composition and activation states via ImmuneSeek™; and baseline survival and stress response pathways via ResistanceSeek™. Through comprehensive proteome-wide characterization, the DynamiQ Normal Human Tissue Proteomics Atlas alleviates reliance on indirect proxy measurements of protein levels, such as RNA expression databases or single-cell RNA sequencing data, and instead provides direct protein quantification.

“The question of where a target is expressed in normal human tissues is one of the most consequential in drug development, and often answered too late, as on-target, off-tissue toxicity is a leading cause of program failure,” said Jonathan Usuka, PhD, MBA, Chief Executive Officer at Sapient. “Our atlas gives teams the baseline biological context to mitigate these liabilities earlier, looking across the dimensions that actually determine therapeutic outcome – so they can make better target selection and safety decisions when they still have the most options.”

“This atlas does not simply catalog which proteins are present in normal tissues – it reveals how proteins are regulated, activated, and organized across normal human biology,” said Mo Jain, MD, PhD, Founder and Chief Scientific Officer at Sapient. “Unlike transcriptomic databases or low-plex immunohistochemistry, we are delivering direct and diverse protein measurements across the proteome – encompassing abundance, surface accessibility, signaling state, immune context, and resistance pathway biology – as a comprehensive reference framework that can be applied from early discovery to target selection, IND-enabling programs, and clinical development.”

The DynamiQ Normal Human Tissue Proteomics Atlas is available through flexible data licensing and proteomics services models, including data access for specific targets, integration with internal workflows, and custom proteomics studies using client-provided samples.

###

About Sapient

Sapient is a leader in multi-omics data generation and insight delivery, providing bespoke services for proteomics, metabolomics, and lipidomics that enable biopharma sponsors to go beyond the genome to accelerate precision drug development.

Utilizing cutting-edge, high-throughput mass spectrometry and biocomputational frameworks, Sapient enables comprehensive biomarker-phenotype mapping across thousands of biosamples for discovery of robust protein, metabolite, and lipid biomarkers, drug targets, and clinical signatures of drug response. The company’s DynamiQ™ Insights Engine – a longitudinal molecular-clinical database collected from tens of thousands of human samples – enables rapid drug target identification, biomarker discovery and validation, and translational and clinical insights across all stages of drug development. For more information, visit sapient.bio.

Media Contact:
Carla Nieser
Head of Marketing, Sapient
carla.nieser@sapient.bio
858.290.7010